June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The multiple effects of mineralocorticoid antagonists for the treatment of retinal diseases
Author Affiliations & Notes
  • Francine F Behar-Cohen
    Ophthalmology, Lausanne University, Jules Gonin Hospital, Lausanne 7, Switzerland
    Team17, UMRS1138, Centre Recherche des Cordeliers, Inserm, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Rocio Herrero-Vanrell
    Faramacia, DEPARTAMENTO DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA, Madrid, Spain
  • Fréderic Jaisser
    Team1, UMRS1138, Centre Recherche des Cordeliers, Inserm U1138, Paris, France
  • Rinath Levy
    Team17, UMRS1138, Centre Recherche des Cordeliers, Inserm, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Alejandro Arboleda
    Team17, UMRS1138, Centre Recherche des Cordeliers, Inserm, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • XinXin Li
    Team17, UMRS1138, Centre Recherche des Cordeliers, Inserm, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Min Zhao
    Team17, UMRS1138, Centre Recherche des Cordeliers, Inserm, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
  • Footnotes
    Commercial Relationships   Francine Behar-Cohen, Inserm Transfert (P); Rocio Herrero-Vanrell, None; Fréderic Jaisser, None; Rinath Levy, None; Alejandro Arboleda, None; XinXin Li, None; Min Zhao, None
  • Footnotes
    Support  Mineraloret project from FRM Mlineraloret, FNS 320030_156401, ANR-15-CE18-0032 ROCK SUR MER-
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4629. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Francine F Behar-Cohen, Rocio Herrero-Vanrell, Fréderic Jaisser, Rinath Levy, Alejandro Arboleda, XinXin Li, Min Zhao; The multiple effects of mineralocorticoid antagonists for the treatment of retinal diseases. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4629.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Both gluco and mineralocorticoid receptors (MR) are expressed in retinal cells, endothelial cells from retinal and choroidal cells and in retinal pigment epithelial cells [Zhao M et al FASEB J. 2010]. In the normal retina, MR activation by aldosterone induces retinal edema and choroidal vasodilation, providing the basis for mineralocorticoid antagonists (MRA) use in central serous chorioretinopathy [Zhao M et al J Clin Invest. 2012].
But the role of MR in pathologic retinal conditions is unclear. Our purpose was to evaluate the role of MR and its antagonism in diabetic retinopathy and choroidal neovascularization in rodents.

Methods : The expression of MR was evaluated in the retina and RPE/ choroid in three animal models of diabetes (type 1 and type 2) and in laser-induced choroidal neovascularization. Aldosterone was measured in the aqueous humor and vitreous of diabetic patients. Marker of MR activation (Ngal/ lipocalin 2) levels were measured in the vitreous of diabetic patients and in the retina of diabetic rodents. The effect of spironolactone on retinal thickness was evaluated in one-year old GK rats.
The effect of MR blockade was assessed in laser-induced choroidal neovascularization (CNV) either with pharmacologic inhibition (local and systemic) or by transgenic mice constructions ( MR flox/flox/Tie2 Cre/+, MR flox/floxLysM Cre/+).
.

Results : In three rodent models of diabetes, MR is over-expressed in the retina and markers of MR activation are elevated . In diabetic patients same markers are elevated in the ocular media and aldosterone is increased. Sustained release of intraocular spironolactone significantly reduced retinal thickness of one-year old GK rats.
In laser-induced CNV, both pharmacologic and transgenic MR inhibition significantly reduced neovascularization in a VEGF-independent manner. MRA and anti-VEGF had synergystic effects.
MRA significantly reduced microglial invasion and activation in the choroid.
No adverse effects resulted from intraocular administration of MRA.

Conclusions :
New mechanisms of action and new molecular targets of MRA have been identified in the retina.
MRA seems promising drugs not only in the tretament of CSCR but also in other retinal diseases associated with macular edema of diverse orignis.
Preliminary results in patients support this hypothesis but clinical trials must be conducted to confirm this hypothesis.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×